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= 581) and bipolar disorder (N = 2421) received quetiapine
monotherapy for at least 4 months at mean initial daily doses of
237 (standard deviation [SD] = 198) mg and 147 (SD = 171) mg,
respectively. Both groups showed negative associations between
initial daily dose and subsequent mental health charges. For
schizophrenia, the relationship approached statistical signiﬁ-
cance (P = 0.1097), with a decrease of $1.28 in mental health
charges for each additional milligram of quetiapine. For bipolar
disorder, the relationship was statistically signiﬁcant (P =
0.0484), with a decrease of $1.31 per additional milligram.
CONCLUSION: This study shows that, in the treatment of
schizophrenia and bipolar disorder, higher doses of quetiapine
may lower levels of mental health resource use, suggesting
enhanced efﬁcacy.
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OBJECTIVES: To estimate the cost acceptability of conventional
antipsychotic (CA) compared to atypical antipsychotic (AA)
treatment for people with broadly deﬁned treatment-resistant or
treatment intolerant schizophrenia in the UK (poor clinical
response or side-effects to one or more antipsychotics, but not
considered for cocaine). METHODS: A total of 227 adults with
broadly deﬁned treatment resistant or intolerant schizophrenia
were enrolled into a pragmatic controlled trial of CA and AA
and randomised to a class of drug (CA or AA). The treating
physician and patient determined the choice of drug within the
class. A societal perspective was used; scheduled follow up was
12 months. The primary outcome was quality adjusted life years
(Daly’s) measured by the Aerosol and population utility tariffs.
Direct costs were measured as resource use multiplied by pub-
lished national unit costs. Censored data were predicted (Cox
regression) and missing observations imputed. Incremental cost
utility ratios (ICER), net beneﬁt statistic and cost acceptability
curves for the intent to teat cohort were calculated. Methods
related assumptions (link between costs and QALYS (stepwise
regression), association between Aerosol and clinical measures
(Spearman’s Rho), imputation method, source of unit costs) were
tested. RESULTS: Utility values were associated with clinical
measures (p < 0.00). QALY’s predicted costs (â = -0.21; p <
0.00). Primary and sensitivity analyses indicated a trend towards
QALY gain (0.04–0.08) and cost savings (£1100–£1200) for CA,
giving a net beneﬁt statistic of £5500 (2.5th–97.5th percentile: —
£2650–£13,000). Complete case analysis indicated a cost of
£3300/QALY. The probability that CA was cost-effective ranged
from 0.64 at a cost/QALY threshold of £0, to 0.78 at a
cost/QALY threshold of £20,000. CONCLUSIONS: The analy-
ses suggest CA is likely to be cost-effective in the UK in 64% of
cases if decision makers are not prepared to pay for an additional
QALY beneﬁt and 78% if they are prepared to pay up to
£20,000/QALY gained.
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OBJECTIVE: To assess the cost-effectiveness of long-acting
risperidone, oral risperidone (RIS), olanzapine (OLA) and
haloperidol decanoate (HAL-DEC) in patients with schizophre-
nia over a 1-year time period. METHODS: Published medical
literature, a consumer health database, and a clinical expert
panel were utilized to populate a decision tree model. The model
captured rates of compliance, relapse, frequency of relapse, dura-
tion of relapse, adverse events, resource utilization and unit cost
of health care resources. Outcomes are expressed in terms of per-
centage, number and duration of relapses per patient per year
and total cost per patient per treatment arm. RESULTS: The pro-
portion of patients predicted by the model to experience a relapse
requiring hospitalization in 1 year were 66% HAL-DEC, 41%
RIS and OLA, 26% long-acting risperidone, while the propor-
tion of patients with an exacerbation not requiring hospitaliza-
tion were 60% HAL-DEC, 37% RIS and OLA, and 24%
long-acting risperidone. The mean number of days of relapse
requiring hospitalization per patient per year were predicted to
be 28 HAL-DEC, 18 RIS and OLA, 11 long-acting risperidone,
while the mean number of days of exacerbation not requiring
hospitalization were 8 HAL-DEC, 5 RIS and OLA, and 3 long-
acting risperidone. This translates into cost savings with long-
acting risperidone compared to oral risperidone, olanzapine, and
haloperidol decanoate of $397, $1742, and $8328, respectively.
CONCLUSIONS: Predictive modeling suggests that long-acting
risperidone can potentially lead to lower rates and fewer days of
symptom exacerbation and hospitalization compared to alterna-
tive treatments. These lower rates translate into cost savings with
the use of long-acting risperidone.
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OBJECTIVE: To compare the utilization of health care resources
for patients with schizophrenia receiving olanzapine versus
risperidone treatment. METHOD: Schizophrenia patients were
drawn from North Carolina Medicaid Claims database. Treat-
ment groups were determined based on the ﬁrst use of olanzap-
ine or risperidone. The use of health care resources was estimated
for schizophrenia-related, mental health-related, and all-cause
services using the negative binomial regression models. The
models were controlled for patient demographic and clinical
characteristics, and resource utilization in the baseline period.
RESULTS: A total of 498 patients (286 in olanzapine cohort and
212 in risperidone cohort) were identiﬁed with available data for
three-month prior and 18-month after antipsychotic treatment.
During the 18-month post-treatment period, patients in olanza-
pine cohort had signiﬁcantly fewer hospital admissions (-0.36,
p = 0.047) and spent signiﬁcantly fewer days in the hospital 
(-0.92, p = 0.018) than risperidone patients for schizophrenia-
related conditions. There were no statistically signiﬁcant differ-
ences between the two cohorts in hospital admissions for mental
health-related and all-cause related conditions. The two groups
did not differ signiﬁcantly in terms of emergency room and
nursing home visits. In addition, patient demographic and clini-
cal characteristics, and resource utilization in prior treatment
period were also found to inﬂuence the use of the medical ser-
vices. CONCLUSIONS: Patients treated with olanzapine are
found to have both fewer hospital admissions and fewer hospi-
tal days for schizophrenia-related conditions as compared to
those treated with risperidone, indicating that olanzapine treat-
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ment may be more effective in reducing schizophrenia-related use
of inpatient services.
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OBJECTIVES: To assess the cost-effectiveness of olanzapine
compared with other antipsychotics in the treatment of schizo-
phrenia in sixteen countries (Algeria, Croatia, Czech Republic,
Hungary, Israel, Latvia, Lithuania, Poland, Romania, Russia,
Saudi Arabia, Slovakia, Slovenia, South Africa, Turkey, and
United Arab Emirates). METHODS: Resource use data from
numerous double-blind randomised controlled trials of olanzap-
ine versus either risperidone or haloperidol were used to deter-
mine treatment costs. Resources considered were study drug,
concomitant medication and hospitalisations. Data relating to
lost production from unemployment and suicide were sourced
from literature. The trials also reported relative safety and efﬁ-
cacy. The doses used were those speciﬁed by the World Health
Organisation. Local prices and costs were applied to resource
utilisation from trials to estimate the overall direct costs associ-
ated with each therapy. Indirect costs were estimated using
average wages and labour data from national statistics ofﬁces.
RESULTS: This analysis, though retrospective, found Olanzi-
pine to be cost-effective or cost saving against haloperidol and
risperidone in all countries considered. The incremental total
cost of olanzapine over risperidone ranged from US$1232
(Israel) to US$470 (Algeria). Against haloperidol, the incremen-
tal total cost ranged from US$2353 (Israel) to US$996
(Romania). Cost-savings were largely driven by reduced hospi-
talisations. In terms of efﬁcacy, meta-analyses showed that com-
pared with risperidone, 10% more olanzapine patients achieved
a ≥40% PANSS improvement; 15% fewer required anticholin-
ergic medication and 12% fewer patients dropped out. Com-
pared to haloperidol these ﬁgures were 8%, 37% and 13%
respectively. These results indicate that olanzapine dominated
risperidone in Czech Republic, Lithuania and Slovakia; and
dominated both risperidone and haloperidol in Croatia,
Hungary, Israel, Saudi Arabia, Slovenia, South Africa and United
Arab Emirates. Olanzapine continued to be cost-effective in sen-
sitivity analyses. CONCLUSIONS: Olanzapine displays greater
efﬁcacy and is cost-effective or cost saving compared with
risperidone and haloperidol in the sixteen countries where analy-
ses were undertaken.
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OBJECTIVE: To determine if total out-of-pocket prescrip-
tion drug (OOPPD) expenditures by the community dwelling
elderly differ according to longitudinal patterns depression.
METHODS: Secondary data analyses were performed using the
population-based study of Assets and Health Dynamics
(AHEAD) of the Oldest Old (adults ≥ 65 years). Depression was
considered present if 4 or more depressive symptoms were
reported on the modiﬁed Center for Epidemiological Studies-
Depression Scale (CES-D). Three survey waves in 1995, 1998
and 2000 allowed depression to be characterized as persistent,
emergent, remittent, and recurrent. ANOVA and regression tech-
niques were used to estimate association between mean total
monthly OOPPD expenditures in 2000 based on depression
pattern. RESULTS: Of the 7027 elderly residents interviewed in
1995, 19% were lost to follow-up at 2000. More than 50% of
respondents never experienced signiﬁcant depressive symptoms.
Mean (SD) OOPPD expenditures for each pattern of depression
were: $221(1203) for recurrent (n = 63); $106(598) for emer-
gent (n = 324); $86(227) for remittent (n = 210); $78(138) for
persistent (n = 179); and $70($168) for never depressed (n =
3290). Only those with recurrent depression had signiﬁcantly
higher OOPPD expenditures compared to those without depres-
sion (ANOVA, p < 0.05). After adjusting for age, gender, and
comorbidity, recurrent and emergent patterns of depression were
associated with signiﬁcantly higher mean monthly OOPPD
expenditures compared to those without depression, while per-
sistent and remittent depression were not. CONCLUSIONS: The
community dwelling elderly with ﬂuctuating patterns of depres-
sion appear to pay more in monthly OOPPD expenditures than
the elderly with stable patterns, including chronic depression.
Upon testing of the robustness of the results using non-para-
metric and longitudinal random-effects models, further investi-
gation into the burden of illness based on longitudinal patterns
of depression is recommended.
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OBJECTIVE: This study provides a proﬁle over time of the incre-
mental health care costs of patients treated for depressive disor-
ders, including attention to medical treatment costs, drug
treatment costs, and incremental treatment costs (i.e., excess
costs as compared to controls) for coexistent medical and psy-
chiatric conditions. METHODS: Administrative claims data
from seven large U.S. companies were used to identify 3464
depressive disorder patients. A random sample of individuals
who were not treated for depressive disorders served as controls.
Incremental cost estimates were generated using a Tobit regres-
sion model including controls for age, gender, health plan, geo-
graphic location, and a number of medical conditions that tend
to precede the onset of depressive disorders. RESULTS: We esti-
mate that treated depressive disorder sufferers incur approxi-
mately $608 per month in incremental health care costs during
their ﬁrst depressive disorder episode. Of this total, 29.4 percent
are due to medical treatment costs, 6.2 percent are due to drug
treatment costs, and 64.4 percent are due to the incremental
treatment costs of coexisting conditions. The costs of treating
subsequent depressive disorder episodes decline. In addition,
while the incremental costs of treating other medical and psy-
chiatric conditions increase in the months prior to the ﬁrst
depression episode, these costs decrease in the months after a
ﬁnal depression episode. CONCLUSION: The health care costs
incurred by treated depressive disorder sufferers in the U.S. are
substantial. Depressive disorder patients experience a “run up”
of costs prior to an episode diagnosis and a subsequent “run
down” in costs after treatment for the condition. Future research
will investigate the indirect costs (i.e., work loss and work
cutback) associated with depressive disorders, as well as the
family burden of depressive episodes using the same time proﬁle
approach developed here.
